Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Flublok

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

- PMLiVE

Xtandi filed as pre-chemo prostate cancer therapy

Astellas and Medivation look to extend uses of their prostate cancer drug

- PMLiVE

Pfizer still number one – just

The PMLiVE Top Pharma List is updated with a ranking of the 25 biggest companies in the industry

- PMLiVE

Sanofi launches online community for midwives

Connecting Midwives follows in the footsteps of the company's Connecting Nurses community

- PMLiVE

FDA scrutiny of alirocumab hits Regeneron and Sanofi

Regulator to assess neurocognitive effects of cholesterol drug

- PMLiVE

Merck joins biosimilar Lantus race

Will work with Samsung to develop version of Sanofi's diabetes medicine

- PMLiVE

Interview: Laure Thibaud, Sanofi

Sanofi’s head of communications talks about her mission to build a team fit for the modern age

Sanofi reception

Sanofi has been light on product launches, says CEO

Drugs launched since 2009 contribute less than €1bn to 2013 turnover

- PMLiVE

NIH forges $230m research alliance with pharma

Brings 10 pharma companies together to speed up research in Alzheimer’s, diabetes and arthritis

Sanofi reception

Sanofi sues Lilly over insulin patents

Challenges development of Lantus biosimilar

- PMLiVE

NICE recommends Sanofi’s oral MS drug

Aubagio backed for NHS use in England and Wales

Sanofi reception

Sanofi forms antibiotic research partnership

Will team up with Germany’s Fraunhofer-Gesellschaft to develop naturally-derived substances

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links